BioCentury
ARTICLE | Product Development

Biogen investors look ahead to Alzheimer’s after Tecfidera IP win

February 5, 2020 10:45 PM UTC
Updated on Feb 6, 2020 at 1:14 AM UTC

The U.S. Patent Trial and Appeal Board removed a major overhang for Biogen investors on Wednesday after ruling to uphold the validity of a patent covering blockbuster MS therapy Tecfidera dimethyl fumarate.

The news sent Biogen Inc. (NASDAQ:BIIB) shares up $47.36 (17%) to $330.65, adding $8.5 billion to the large cap’s valuation...

BCIQ Company Profiles

Biogen Inc.